NCT03228667Phase 2Active not recruiting

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Study sponsor: ImmunityBio, Inc. · IBRX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-08-31Estimated
Enrollment · participants40Estimated
Source updated2026-01-14Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Objective Response Rate Measure: Prolongation of Overall Survival (OS) with NAI Therapy by ALC Response. After: Measure: ORR, defined as Investigator-assessed CR + PR per RECIST v1.1. Measure: Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview